APA

Fabris M., Quartuccio L., Fabro C., Sacco S., Lombardi S., Ramonda R., Biasi D., Punzi D., Adami S., Olivieri I., Curcio F. & De Vita S. (20170309). The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. : The pharmacogenomics journal.

Chicago

Fabris M, Quartuccio L, Fabro C, Sacco S, Lombardi S, Ramonda R, Biasi D, Punzi D, Adami S, Olivieri I, Curcio F and De Vita S. 20170309. The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. : The pharmacogenomics journal.

Harvard

Fabris M., Quartuccio L., Fabro C., Sacco S., Lombardi S., Ramonda R., Biasi D., Punzi D., Adami S., Olivieri I., Curcio F. and De Vita S. (20170309). The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. : The pharmacogenomics journal.

MLA

Fabris M, Quartuccio L, Fabro C, Sacco S, Lombardi S, Ramonda R, Biasi D, Punzi D, Adami S, Olivieri I, Curcio F and De Vita S. The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. : The pharmacogenomics journal. 20170309.